Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback